Better control of airway inflammation with SINGULAIR and fluticasone vs. salmeterol with fluticasone in a substudy of 41 asthma patients.4
- 40% reduction in a key marker of airway inflammation (sputum eosinophils)
IN 2 STUDIES IN ADULT ASTHMATICS WITH A HISTORY OF EXERCISE-INDUCED ASTHMA...
No attenuation of response to rescue therapy.
The response to rescue therapy with a short-acting beta2-agonist was significantly diminished among patients receiving salmeterol (p<0.001 vs. placebo; n=119).16
No tolerance
The bronchoprotective effects of salmeterol were significantly diminished over time (p=0.017 vs. baseline; N=191).17
*
IMPACT=Investigation of Montelukast as a Partner Agent for Complementary Therapy18
**
A randomized, double-blind, double-dummy, parallel-group study that enrolled men and women aged 15 to 72 years with a clinical history of chronic asthma for <1 year. The included-sputum subgroup analysis was conducted in 41 patients from four centers to assess airway inflammation by marker assays.4
***
Asthma attacks were defined as worsening asthma requiring an unscheduled visit to a doctor, emergency department, or hospital, or treatment with oral, intravenous, or intramuscular corticosteroids. The number of patients who had asthma attacks during 48 weeks of treatment was 150 (20.1%) in the SINGULAIR group, and 142 (19.1%) in the salmeterol with fluticasone group (modified intent-to-treat analysis).4
Better control of airway inflammation with SINGULAIR and fluticasone vs. salmeterol with fluticasone in a substudy of 41 asthma patients.
